Safety and Efficacy of Tegaserod in Opioid-induced Constipation in Patients With Non-cancer Pain.

Inclusion Criteria: * Male and female outpatients 18 years of age or older. * Patients with chronic non-cancer pain that necessitates the use of non- injectable opioid analgesics. * Chronic pain which has been present for a minimum of 3 months which needs the chronic use of opioids for pain relief. * Constipation, according to the investigator's clinical judgment, that is resulting from opioid use for non-cancer chronic pain. Opioid-induced Constipation (OIC) is defined as follows: less than 3 spontaneous bowel movements per week and at least one of the following on at least 25% of occasions: 1. Hard or very hard stools 2. sensation of incomplete evacuation 3. straining while having a bowel movement Exclusion Criteria: * 1\. Who are receiving opioids for abdominal pain or connective tissue disorders. * Planned discontinuation of opioids during the study * Who underwent major surgery within 3 months prior to screening. * With a history of prior chronic constipation (CC) that was present for more than three months and that was not related to opioid use. * With a current diagnosis of irritable bowel syndrome (IBS) constipation predominant or alternators. * With a previous use of tegaserod within 3 months prior to baseline. Other protocol-defined inclusion/exclusion criteria may apply